UK markets close in 2 hours 43 minutes
  • FTSE 100

    6,930.51
    -54.08 (-0.77%)
     
  • FTSE 250

    16,901.87
    -402.24 (-2.32%)
     
  • AIM

    804.41
    -16.94 (-2.06%)
     
  • GBP/EUR

    1.1134
    -0.0042 (-0.37%)
     
  • GBP/USD

    1.0676
    -0.0055 (-0.52%)
     
  • BTC-GBP

    17,868.40
    -1,234.42 (-6.46%)
     
  • CMC Crypto 200

    435.99
    -23.15 (-5.04%)
     
  • S&P 500

    3,647.29
    -7.75 (-0.21%)
     
  • DOW

    29,134.99
    -125.82 (-0.43%)
     
  • CRUDE OIL

    79.93
    +1.43 (+1.82%)
     
  • GOLD FUTURES

    1,645.20
    +9.00 (+0.55%)
     
  • NIKKEI 225

    26,173.98
    -397.89 (-1.50%)
     
  • HANG SENG

    17,250.88
    -609.43 (-3.41%)
     
  • DAX

    12,015.38
    -124.30 (-1.02%)
     
  • CAC 40

    5,690.21
    -63.61 (-1.11%)
     

Allergy Therapeutics' (LON:AGY) investors will be pleased with their favorable 55% return over the last three years

·3-min read

Allergy Therapeutics plc (LON:AGY) shareholders might be concerned after seeing the share price drop 25% in the last quarter. But don't let that distract from the very nice return generated over three years. After all, the share price is up a market-beating 55% in that time.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

See our latest analysis for Allergy Therapeutics

Because Allergy Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Allergy Therapeutics' revenue trended up 4.3% each year over three years. That's not a very high growth rate considering it doesn't make profits. In that time the share price is up 16% per year, which is not unreasonable given the revenue gorwth. Ultimately, the important thing is whether the company is trending to profitability. In this sort of situation it can be worth putting the stock on your watchlist. If it can become profitable, then even moderate revenue growth could grow profits quickly.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at Allergy Therapeutics' financial health with this free report on its balance sheet.

A Different Perspective

Although it hurts that Allergy Therapeutics returned a loss of 30% in the last twelve months, the broader market was actually worse, returning a loss of 47%. Unfortunately, last year's performance may indicate unresolved challenges, given that it's worse than the annualised loss of 7% over the last half decade. Whilst Baron Rothschild does tell the investor "buy when there's blood in the streets, even if the blood is your own", buyers would need to examine the data carefully to be comfortable that the business itself is sound. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for Allergy Therapeutics you should be aware of, and 1 of them doesn't sit too well with us.

But note: Allergy Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here